Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Tecovirimat Oral Capsule
DRUG
3 trials
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
, Miquel Ekkelenkamp
Conditions
MPOX
Monkeypox
Phase 2
Tecovirimat for Treatment of Monkeypox Virus
Completed
NCT05559099
National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Start: 2022-10-10
End: 2024-09-03
Updated: 2025-10-09
Phase 3
Study of Tecovirimat for Human Mpox Virus
Terminated
NCT05534984
National Institute of Allergy and Infectious Diseases (NIAID)
MPOX
Start: 2022-09-08
End: 2025-02-22
Updated: 2026-06-23
Phase 4
European Trial Into Mpox Infection
Recruiting
NCT06156566
Miquel Ekkelenkamp
Monkeypox
Start: 2024-08-09
End: 2026-08-31
Target: 150
Updated: 2025-03-28
Related Papers
Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial.
2026-07-29
Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo
New England Journal of Medicine
2025-04-16
56 citations
MOSAIC: A cohort study of human mpox virus disease.
2023-12-12
2 citations
Intersecting HIV and mpox epidemics: more questions than answers
Journal of the International AIDS Society
2022-12-01
16 citations
Monkeypox: Challenging Clinical Questions
Annals of Internal Medicine
2022-10-14
2 citations